Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The biggest M&A deal in India's drug industry for 2024, involving the acquisition of JB Chemicals, is on the verge of being withdrawn. Sources indicate that all contenders have either withdrawn or are considering canceling their plans. Anurag Joshi provided details on the matter. The Alkem promoter stake sale is aimed at the JB Chemicals bid.
#MarketsWithMC | Alkem Labs in talks to acquire Novartis AG's India unit: CNBC-TV18 💰🔄 Tap for more details👇 https://t.co/KFb5u3SbOC #AlkemLabs #Novartis #Acquisition
#NewsFlash | Alkem Labs in discussions to buy Novartis India from its Swiss parent. Total value of the deal expected to be around ₹2,000 crore, sources to @R_Dhanrajani - Alert: DRL, Zydus also in fray to buy the India arm of Novartis AG - Alert: CNBC-TV18 reached out to… https://t.co/KzV5DNp3be
Wow. Don't know how to interpret this.... Removing J&J as a potential strategic acquirer is huge. https://t.co/rGr7qVtgaK
